GSK reports fall in profit over Zantac fallout—but boosts 2031 revenue target to £40 billion due to boom in cancer drug sales

[
“We expect another year of profitable growth in 2025, and have further improved our long-term outlook,” said CEO Walmsley. Read More
https://fortune.com/img-assets/wp-content/uploads/2025/02/GettyImages-2173420062-e1738748622764.jpg?resize=1200,600
https://fortune.com/europe/2025/02/05/gsk-profits-zantac-2031-revenue-targets-boost-cancer-drug-sales-emma-walmsley-fortune-500-europe/


AFP